These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25863582)

  • 21. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
    Lee DW; Jang MJ; Lee KH; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY
    Br J Cancer; 2016 Nov; 115(10):1201-1205. PubMed ID: 27736843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
    Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
    Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
    Colloca G; Venturino A
    Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 26. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer.
    Yoshida Y; Kaneko M; Narukawa M
    Int J Clin Oncol; 2020 May; 25(5):851-860. PubMed ID: 31950377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.
    Petrelli F; Barni S
    Ann Oncol; 2013 Jan; 24(1):186-92. PubMed ID: 22898038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of surrogate end points for overall survival in advanced colorectal cancer: further need for clarification: Letter to the editor on: Ciani et al., 2015, Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. 2015, J Clin Epidemiol 68:833-842.
    Schürmann C; Wieseler B
    J Clin Epidemiol; 2016 Feb; 70():278-9. PubMed ID: 26348800
    [No Abstract]   [Full Text] [Related]  

  • 32. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
    Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
    Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
    Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
    JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.
    Chirila C; Odom D; Devercelli G; Khan S; Sherif BN; Kaye JA; Molnár I; Sherrill B
    Int J Colorectal Dis; 2012 May; 27(5):623-34. PubMed ID: 22076612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.
    Cartier S; Zhang B; Rosen VM; Zarotsky V; Bartlett JB; Mukhopadhyay P; Wagner S; Davis C
    Oncol Res Treat; 2015; 38(3):88-94. PubMed ID: 25792079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
    Liang F; Zhang S; Wang Q; Li W
    Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
    Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
    J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
    Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
    Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.